Sclerosteosis

Sclerosteosis is an extremely rare, progressive sclerosing bone dysplasia classified among the craniotubular hyperostoses.[1] It is caused by loss-of-function mutations in the SOST gene (sclerosteosis type 1) or the LRP4 gene (sclerosteosis type 2), both of which result in deficiency of sclerostin-mediated inhibition of the canonical Wnt signaling pathway, leading to unchecked osteoblastic bone formation throughout life.[1][2][3] The disorder follows autosomal recessive inheritance and produces generalized hyperostosis and sclerosis most pronounced in the skull, mandible, and tubular bones.[1] The signature radiographic pattern is diffuse widening and increased density of the calvarium, skull base, and mandible with cortical thickening of the long bones. Management is symptomatic and primarily surgical, as no disease-specific medical therapy is available.[1]

Sclerosteosis is the accepted name in current nosology. Two genetic subtypes are recognized:[4]

• Sclerosteosis type 1 (SOST1): caused by homozygous loss-of-function mutations in the SOST gene on chromosome 17q12-q21[2][3]
• Sclerosteosis type 2 (SOST2): caused by loss-of-function mutations in the LRP4 gene[4]

Sclerosteosis and van Buchem disease (endosteal hyperostosis, van Buchem type) are collectively termed SOST-related sclerosing bone dysplasias.[1] Van Buchem disease is the milder allelic disorder caused by a noncoding deletion of a SOST regulatory element rather than coding mutations.[5] Older synonyms include hyperostosis corticalis generalisata.[6] The term "craniodiaphyseal dysplasia" is a distinct entity and should not be used interchangeably, although heterozygous SOST mutations have been identified in some cases of craniodiaphyseal dysplasia.[1]

Sclerosteosis is one of the rarest skeletal dysplasias. Approximately 100 individuals have been reported worldwide, of whom 66 were from South Africa.[1] The disorder is most prevalent in the Afrikaner population due to a founder variant, with an estimated carrier rate of 1:100 and prevalence of approximately 1:60,000.[1] Founder variants have also been identified in families from Brazil and Turkey.[1] Sporadic cases have been reported in individuals of Chinese, Indian Tamil, Senegalese, and other ethnic backgrounds.[3][4][7] Males and females are equally affected. Skeletal features typically become apparent in early childhood, though syndactyly is present at birth.[1]

Presentation and Tempo

Affected individuals appear normal at birth except for syndactyly, which is present in approximately two-thirds of cases and most often involves the second and third fingers.[1] Skeletal overgrowth becomes clinically evident in early childhood and progresses into adulthood, with complications generally stabilizing in the third decade.[1]

Craniofacial and Oral Findings

• Facial distortion from frontal bossing and asymmetric mandibular overgrowth is characteristic, affecting approximately 90% of individuals[1]
• Proptosis, hypertelorism, and midfacial hypoplasia occur in some patients[1]
• Teeth are structurally and mechanically normal, but malalignment and malocclusion result from mandibular hyperostosis[1][8]
• Maxillary (palatal) and mandibular tori are characteristically present[8]
• Partial anodontia and delayed eruption have been reported occasionally[8]
• Tooth extraction is technically difficult due to the extreme density and thickness of the jaws; however, post-extraction osteomyelitis has not been recorded[8][9]
• Drooling and masticatory difficulty are common consequences of facial nerve palsy and mandibular overgrowth[8]

Cranial Nerve Complications

• Recurrent facial palsies (CN VII) are the hallmark complication, affecting 93% of individuals, with onset in early childhood[1]
• Hearing loss affects 94% of individuals, beginning as conductive loss in childhood and often progressing to mixed conductive-sensorineural loss[1]
• Less common entrapment syndromes include visual loss (CN II), trigeminal neuralgia or anosmia (CN V), and sensorineural hearing loss (CN VIII)[1]

Systemic Features

• Tall stature with accelerated linear growth; adults may exceed 2 meters[1]
• Syndactyly ranging from soft-tissue webbing to bony phalangeal fusion, with occasional nail dysplasia or aplasia[1]

Red Flags

Increased intracranial pressure from calvarial thickening develops in approximately 71% of individuals, typically beginning in late adolescence, and is the leading cause of death.[1] Sudden death from brainstem herniation is a recognized risk.[1][7]

Location and Distribution

Sclerosteosis produces a generalized skeletal pattern with the most pronounced changes in the calvarium, skull base, and mandible.[1][2] The maxilla, clavicles, ribs, pelvis, scapulae, and all long bones are also involved.[1] In the jaws, the mandible is characteristically more severely affected than the maxilla, with gross asymmetric enlargement.[8][9]

Periphery and Shape

The hyperostotic bone shows smooth, broad expansion of the outer contours of the calvarium and mandible rather than focal or lobulated masses.[1] The mandibular body and rami are widened, and the overall mandibular contour is enlarged and distorted.[9][10] Unlike the craniotubular dysplasias, the predominant feature is overgrowth of bone leading to altered contours with increased radiologic density.[1]

Internal Architecture

The internal architecture is uniformly dense and sclerotic. The calvarium demonstrates diffuse, homogeneous sclerosis with loss of the normal diploic space.[7] In the mandible and maxilla, the trabecular pattern is replaced by dense, sclerotic bone.[1][2] The sclerosis is not associated with abnormal mineralization, distinguishing it from osteopetrosis.[1] Bone mineral density measured by DXA is markedly elevated, with z-scores ranging from 7.7 to 14.4 SD above the mean at the spine.[1]

Effects on Teeth and Adjacent Structures

• Teeth are morphologically normal but become malaligned and maloccluded due to the progressive mandibular and maxillary hyperostosis[1][8]
• Maxillary and mandibular tori are characteristically present in all affected individuals[8]
• Cranial nerve foramina are progressively narrowed by bone overgrowth, producing the characteristic nerve entrapment syndromes[1][11]
• The orbital volume is reduced by hyperplasia and sclerosis of the orbital bones, contributing to proptosis[7]
• Paranasal sinuses may be obliterated or reduced in volume by the encroaching hyperostotic bone

Cortical Involvement and Extent

Cortical thickening is a hallmark finding in the tubular bones. The metacarpals, phalanges, radii, ulnae, and humeri demonstrate marked cortical thickening with undermodeling of the diaphyses.[1][7] The clavicles and ribs appear broad and dense.[1] The scapulae and pelvis show sclerosis without significant increase in size.[1]

Growth Pattern

The hyperostosis is progressive throughout childhood and adolescence, with the rate of bone overgrowth appearing to stabilize in the third decade.[1] The intracranial cavity progressively narrows as the calvarium thickens, which is the mechanism underlying the life-threatening elevation of intracranial pressure.[1]

Variants

Sclerosteosis type 2 (LRP4-related) tends to produce a milder skeletal phenotype than type 1 but more striking syndactyly with bony fusion of digits.[4] Significant phenotypic heterogeneity can occur even among siblings carrying identical SOST mutations.[7]

Medical CT

CT of the skull demonstrates generalized thickening of the cranial vault with homogeneous sclerosis and loss of the diploic space.[7] Axial and coronal CT sections reveal narrowing of the cranial nerve foramina, reduced orbital volume with orbital bone hyperplasia and sclerosis, and progressive reduction of the intracranial cavity.[7] CT is essential for surgical planning, particularly for craniectomy and cranial nerve decompression procedures.[11]

MRI

MRI of the brain may reveal ventricular compression, flattened pituitary gland with elongated pituitary stalk, and absent cerebral convolutions in severe cases, reflecting the reduced intracranial volume.[7] MRI is valuable for assessing the degree of brainstem compression and monitoring intracranial pressure effects.[11]

Sclerosteosis must be distinguished from other sclerosing bone dysplasias. The combination of generalized progressive hyperostosis with mandibular overgrowth, syndactyly, tall stature, and cranial nerve entrapment is highly characteristic. The key differential considerations involve other craniotubular hyperostoses and osteoscleroses.

The highest-risk diagnostic pitfall is confusion with osteopetrosis, which shares generalized osteosclerosis and cranial nerve complications but differs fundamentally in pathogenesis (osteoclast dysfunction versus osteoblast hyperactivity), lacks bone overgrowth and contour alteration, and carries a risk of bone fragility and osteomyelitis not seen in sclerosteosis.[1] Genetic testing for SOST and LRP4 mutations provides definitive diagnosis.[1]

Bone biopsy in sclerosteosis reveals increased bone volume with thickened cortices and trabeculae.[1] Osteoblastic bone formation is increased, while osteoclastic bone resorption is normal or decreased.[1][11] Mineralization of bone tissue is normal, which is an important distinction from osteopetrosis where abnormal mineralization is characteristic.[1] The high bone density results from excessive deposition of structurally normal lamellar bone rather than from retention of calcified cartilage or defective remodeling.[1] Osteoid seams may be evident throughout the facial skeleton, reflecting the increased extracellular matrix production by sclerostin-deficient osteoblasts.[10] The bone demonstrates increased biomechanical competence and resistance to fractures.[1] The risk of osteomyelitis or bone marrow failure is not increased.[1]

The molecular basis is loss of sclerostin function. Sclerostin, encoded by SOST, is a glycoprotein secreted predominantly by osteocytes that inhibits canonical Wnt signaling by binding to LRP5/6 coreceptors.[1][13] Loss-of-function mutations remove this inhibitory brake on osteoblast-mediated bone formation.[1] In sclerosteosis type 2, mutations in LRP4 disrupt the sclerostin-LRP4 interaction required for sclerostin's inhibitory activity.[1][4]

Workup and Referral

Diagnosis is suspected clinically and radiographically and confirmed by molecular genetic testing of SOST and LRP4.[1] Early identification of homozygotes in affected families is critical for monitoring and prevention of complications.[11] Referral to a multidisciplinary team including neurosurgery, otolaryngology, ophthalmology, orthodontics, and craniofacial surgery is essential.[1]

Surveillance

• Bone mineral density and biochemical markers of bone turnover: intermittently until age 18, then every 5 years[1]
• Audiologic assessment: annually in childhood, as needed in adults[1]
• Cranial nerve entrapment and intracranial pressure evaluation: every 6 months until age 18, then annually[1]